CA2375508A1 - Methods and products for manipulating uncoupling protein expression - Google Patents

Methods and products for manipulating uncoupling protein expression Download PDF

Info

Publication number
CA2375508A1
CA2375508A1 CA002375508A CA2375508A CA2375508A1 CA 2375508 A1 CA2375508 A1 CA 2375508A1 CA 002375508 A CA002375508 A CA 002375508A CA 2375508 A CA2375508 A CA 2375508A CA 2375508 A1 CA2375508 A1 CA 2375508A1
Authority
CA
Canada
Prior art keywords
ucp
cell
plasma membrane
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375508A
Other languages
English (en)
French (fr)
Inventor
Martha K. Newell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Vermont
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375508A1 publication Critical patent/CA2375508A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
CA002375508A 1999-06-23 2000-06-22 Methods and products for manipulating uncoupling protein expression Abandoned CA2375508A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14057499P 1999-06-23 1999-06-23
US60/140,574 1999-06-23
PCT/US2000/017245 WO2000078941A2 (en) 1999-06-23 2000-06-22 Methods and products for manipulating uncoupling protein expression

Publications (1)

Publication Number Publication Date
CA2375508A1 true CA2375508A1 (en) 2000-12-28

Family

ID=22491870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375508A Abandoned CA2375508A1 (en) 1999-06-23 2000-06-22 Methods and products for manipulating uncoupling protein expression

Country Status (9)

Country Link
US (2) US7816319B2 (https=)
EP (1) EP1194168B1 (https=)
JP (1) JP2003503319A (https=)
AT (1) ATE462447T1 (https=)
AU (1) AU780815B2 (https=)
CA (1) CA2375508A1 (https=)
DE (1) DE60044087D1 (https=)
HK (1) HK1047032A1 (https=)
WO (1) WO2000078941A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
ATE462447T1 (de) 1999-06-23 2010-04-15 Univ Vermont Verfahren und mittels zur manipulierung der expression des uncoupling proteins
GB9930100D0 (en) * 1999-12-17 2000-02-09 Smithkline Beecham Plc New use
CA2534816A1 (en) 2003-06-12 2004-12-23 Evan Newell Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
CA2602562C (en) 2005-03-25 2015-07-07 Alt Solutions, Inc. Modulation of telomere length in telomerase positive cells and cancer therapy
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
US8329753B2 (en) * 2005-05-02 2012-12-11 The Regents Of The University Of Colorado Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition
CN101588805A (zh) 2005-05-18 2009-11-25 Alt解决方案公司 为预防和治疗癌症对癌细胞中端粒长度的药理学调节
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
GB0610317D0 (en) * 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2009021034A2 (en) * 2007-08-06 2009-02-12 University Of Rochester Methods of treating b-cell cancers
CA2716321A1 (en) * 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
WO2010051347A1 (en) * 2008-10-31 2010-05-06 David Sheikh-Hamad A method for cardioprotection
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
AU2010330823A1 (en) * 2009-12-18 2012-07-05 Joslin Diabetes Center, Inc. Beta-cell replication promoting compounds and methods of their use
US9938279B2 (en) * 2013-04-09 2018-04-10 Energenesis Biomedical Co., Ltd Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935450A (en) 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
US4724234A (en) 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
WO1994028897A2 (en) 1993-06-07 1994-12-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection
CA2260766A1 (en) 1996-07-12 1998-01-22 Emory University Regulation of apoptosis and in vitro model for studies thereof
AU2809797A (en) * 1997-01-15 1998-08-07 Centre National De La Recherche Scientifique Centre De Recherche Sur L'endocrinologie Moleculaire Et Le Developpement Respiration uncoupling protein
AU6585498A (en) * 1997-04-04 1998-10-30 Amylin Pharmaceuticals, Inc. Novel uncoupling protein and methods of use
AU7466198A (en) * 1997-04-09 1998-10-30 Beth Israel Deaconess Medical Center Ucp3: an uncoupling protein homologue
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
JP2002536009A (ja) 1999-02-09 2002-10-29 レキシコン・ジェネティクス・インコーポレーテッド ヒト脱共役タンパク質およびそれをコードするポリヌクレオチド
ATE462447T1 (de) 1999-06-23 2010-04-15 Univ Vermont Verfahren und mittels zur manipulierung der expression des uncoupling proteins
US7105718B2 (en) 2000-03-31 2006-09-12 The Regents Of The University Of Colorado Compositions and methods for regulating metabolism in plants
JP2006512041A (ja) 2001-10-12 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト 活性酸素を用いる共刺激分子発現の調節のための方法
US7341559B2 (en) * 2002-09-14 2008-03-11 Masimo Corporation Pulse oximetry ear sensor

Also Published As

Publication number Publication date
AU780815B2 (en) 2005-04-21
WO2000078941A2 (en) 2000-12-28
WO2000078941A3 (en) 2001-02-22
HK1047032A1 (zh) 2003-02-07
US20110206755A1 (en) 2011-08-25
JP2003503319A (ja) 2003-01-28
EP1194168B1 (en) 2010-03-31
ATE462447T1 (de) 2010-04-15
DE60044087D1 (de) 2010-05-12
US20060247199A1 (en) 2006-11-02
EP1194168A2 (en) 2002-04-10
US7816319B2 (en) 2010-10-19
AU5760000A (en) 2001-01-09

Similar Documents

Publication Publication Date Title
US20110206755A1 (en) Methods and products for manipulating uncoupling protein expression
US11529416B2 (en) Vista modulators for diagnosis and treatment of cancer
JP6665139B2 (ja) 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
KR101882523B1 (ko) Ｖｉｓｔａ 조절 ｔ 세포 매개 단백질, ｖｉｓｔａ 결합제 및 그것의 용도
US7029674B2 (en) Methods for downmodulating immune cells using an antibody to PD-1
JP4903128B2 (ja) Ｔｉｍ−１、ｔｉｍ−２、およびｔｉｍ−４の機能を調節することによって免疫応答を調節する方法
US20170184604A1 (en) Dd1alpha receptor and uses thereof in immune disorders
US9834610B2 (en) Fusion proteins for modulating regulatory and effector T cells
NZ275711A (en) Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type)
WO2015116178A1 (en) Fusion proteins for modulating regulatory and effector t cells
AU2005203138B2 (en) Methods and products for manipulating uncoupling protein expression
HK40015742A (en) Vista modulators for diagnosis and treatment of cancer
Maxwell The role of costimulation and adjuvants in the development of T cell effector and memory responses
HK1214272B (en) Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued